投資概要
業績高增長預期
公司前三季度銷售額同比增長21%，超出我們的預期。主要是因為：1）創新藥銷售增長迅速，收入占比不斷提升；2）咖啡因及其他板塊增長迅速，收購的葡萄糖業務貢獻收入；3）維生素C延續中期以來的高增長。三季報顯示利潤率得到顯著提升，毛利率提高8.3個百分點，得益於創新藥等高毛利藥品銷售占比提升。預計公司2017、2018年銷售與淨利潤增長在20%-30%左右。
Graduated from Hong Kong Polytechnic University, Master of Finance (Investment Management). Possess bachelor degree majoring in Financial Management from Southwestern University of Finance and Economics. Focus on industry prospect and corporate fundamentals to explore investment value and cover pharmaceutical and consumer industry.
